GSK Rotavirus Vaccine Phase III Safety Trials Will Enroll 50,000 Children
Executive Summary
GlaxoSmithKline will evaluate the rotavirus vaccine Rotarix in 50,000 children in Phase III safety trials set to begin at the end of 2001, Biologicals President Jean Stephenne told a London analysts conference Feb. 22.